Testing fostamatinib for lung transplant patients with donor-specific antibodies
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a new medicine called fostamatinib for people who have had a lung transplant and have developed donor-specific antibodies (DSA) on their lung. The goal is to see if this medicine is safe and can help prevent the body from rejecting the new lung.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- This must be your first lung transplant.
- You must have donor-specific antibodies (DSA) in your blood after day 21 following your transplant, but your lungs must still be working well.
- Your liver function, blood counts, and kidney function must meet certain levels (e.g., adequate liver enzymes, enough white blood cells, hemoglobin at least 9 g/dL, and kidney function estimated >30 mL/min).
- If you are a woman who could become pregnant, you must have a negative pregnancy test and use two effective forms of birth control, or be abstinent, during the study and for 28 days after the last dose.
- You must not have other serious medical conditions (e.g., active infections, uncontrolled high blood pressure, recent drug-induced liver problems, or certain cancers within the past 5 years).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune-suppressing medicine to stop a serious complication called primary graft dysfunction that can happen soon after a lung transplant. It may help people who are already on the transplant waiting list and plan to receive a standard anti-rejection drug regimen.
This study tests whether the drug LAM-001 can help people who have developed a condition called bronchiolitis obliterans syndrome (BOS) after a double lung transplant. BOS causes a slow decline in lung function, and this trial aims to see if LAM-001 can slow or stop that decline.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
This trial tests a drug called fostamatinib to see if it can help people with a severe lung condition called ARDS, which causes breathing failure. If you are in the hospital on a breathing machine, this drug might help your lungs recover.
This study looks for lab “clues” that can help predict how well someone’s lungs will do after a lung transplant. It may help doctors spot transplant-related problems earlier so care can be planned sooner.
Hear when a new Lung Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.